aTyr Pharma, Inc.(US:ATYR) Prnewswire·2025-10-31 12:45Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between January 16, 2025, and September 12, 2025 [1] - The lawsuit claims that aTyr misled investors regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage completely [2] - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a significant stock price drop of 83.2% from $6.03 to $1.02 per share in one day [2] Case Details - The lawsuit seeks to recover losses for investors who were adversely affected by the alleged fraud [1] - The primary endpoint that was not met involved the change from baseline in mean daily OSC dose at week 48 [2] - Following the disappointing results, aTyr plans to engage with the FDA to determine the next steps [2] Next Steps - Investors who suffered losses during the relevant time frame have until December 8, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no costs or obligations for class members [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]